Why Ionis Pharmaceuticals, Inc. (IONS) stock moved
Ionis Pharmaceuticals, Inc. (IONS) shares tumbled 24.3% to $29.85 as of November 9, 2026, a sharp decline from the prior close of $39.42. BestStocks flagged the session as a major change for IONS. The move is tied to an earnings beat. Below, we break down what changed for IONS, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
Earnings Beat
Ionis Pharmaceuticals, Inc. (IONS) reported EPS of −$0.66 vs. consensus estimate of −$1.22 for Q3 FY2026, beating expectations by 45.9%. Monitor for management commentary on full-year 2026 guidance and cash burn trajectory in upcoming earnings calls or investor materials.
What it means for Ionis Pharmaceuticals, Inc. investors
For Ionis Pharmaceuticals, Inc. investors, the recent signals add up to a strong bearish shift. On the constructive side: Earnings beat — stock sold off (sell-the-news reaction). Weighing against that: Sharp 24.3% decline — elevated risk; High volume 3.0x on decline — distribution signal. Wall Street's consensus price target sits at $84.92, implying +184.5% upside from $29.85. Over the past 90 days analysts logged 2 upgrades and 1 downgrade. BestStocks rates the overall signal quality high (90/100). With earnings roughly 107 days out, the next report is the most likely near-term test of the move.
IONS price reaction
IONS last traded at $29.85, down $9.57 (-24.28%) from the previous close of $39.42. The session traded on 3.0× average volume (very high), so the move carried above-average conviction. Over the past month the stock has ranged between $29.85 and $45.40, and it currently sits about 0% of the way up that band.
Bullish and bearish analyst opinions on Ionis Pharmaceuticals, Inc. (IONS)
The consensus analyst price target on Ionis Pharmaceuticals, Inc. (IONS) is $84.92, 184.5% above the recent $29.85. Over the past 90 days analysts logged 2 upgrades, 13 maintains, and 1 downgrade. Here is how the bullish and bearish cases on IONS line up.
The bullish case
- Wall Street's consensus price target of $84.92 implies +184.5% upside from $29.85.
- The Street's most bullish target is $115.00 (+285.3%).
- 2 analyst upgrades in the past 90 days, most recently BMO Capital to Outperform (2026-10-22).
- Earnings beat — stock sold off (sell-the-news reaction).
The bearish case
- 1 analyst downgrade in the past 90 days, most recently BMO Capital to Market Perform (2026-08-19).
- Sharp 24.3% decline — elevated risk.
- High volume 3.0x on decline — distribution signal.
- Ionis Pharmaceuticals slashed its TRYNGOLZA sales forecast by 50%, overshadowing otherwise solid Q3 earnings that beat revenue estimates, according to Barron's.
Weighing both sides, BestStocks' composite read of recent signals is strongly bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Nov 9, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for IONS
In-depth IONS event analyses
Frequently asked questions about IONS
Why did Ionis Pharmaceuticals, Inc. (IONS) stock move?
IONS tumbled 24.3% to $29.85. The move is associated with an earnings beat.
How much did IONS stock fall?
IONS lost 24.28% ($9.57) versus the prior close of $39.42, last trading at $29.85 on 3.0× average volume.
When is Ionis Pharmaceuticals, Inc.'s next earnings date?
IONS's next earnings report is estimated for 2027-02-24 — about 107 days away.
What is the analyst price target for IONS?
The consensus analyst price target for IONS is $84.92, about 184.5% above the current $29.85. Over the past 90 days, analysts recorded 2 upgrades, 13 maintains, and 1 downgrade.
How BestStocks tracks IONS
This page is generated automatically by BestStocks' change-detection system after an earnings beat was detected and verified against independent data sources. It draws on 20 tracked change events for IONS, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 9, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
